The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) brings together Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceuticals to advance academic drug discovery and support medical breakthroughs. The institute achieves this aim by removing barriers that impede the drug discovery process by providing investigators with the tools, technology and expertise to go from a groundbreaking discovery or biologic insight to a validating proof-of-concept study, while retaining control over intellectual property. Tri-I TDI investigators have worked on early-stage drug discovery projects spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases. In addition to this research support, Tri-I TDI also offers training through the Sanders Innovation and Education Initiative, which includes an entrepreneurship course, medicinal chemistry course and an ongoing lecture series covering noteworthy advances in the biomedical sciences.
